ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Purdue licenses Exicure drug

by Lisa M. Jarvis
December 19, 2016 | APPEARED IN VOLUME 94, ISSUE 49

Purdue Pharma has formed a pact with Exicure, a biotech firm developing “spherical nucleic acid” technology, which facilitates intracellular delivery of nucleic acids by tethering them to the surface of a nanoparticle. In exchange for an undisclosed payment and equity investment, Exicure will grant Purdue rights to its lead compound, AST-005, a topically applied treatment for psoriasis that has completed a Phase I study. Exicure is based on technology developed in the labs of Northwestern University chemist Chad Mirkin.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment